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Deletion of phenylalanine 508 (F508) accounts for nearly 70%
of all mutations that occur in the cystic fibrosis transmembrane
conductance regulator (CFTR). The F508 mutation is a class II
processing mutation that results in very little or no mature CFTR
protein reaching the apical membrane and thus no cAMP-mediated
Cl conductance. Therapeutic strategies have been developed to
enhance processing of the defective F508 CFTR molecule so that
a functional cAMP-regulated Cl channel targets to the apical mem-
brane. Sarcoplasmic/endoplasmic reticulum calcium (SERCA) inhib-
itors, curcumin and thapsigargin, have been reported to effectively
correct the CF ion transport defects observed in the F508 CF mice.
We investigated the effect of these compounds in human airway
epithelial cells to determine if they could induce F508 CFTR matu-
ration, and Cl secretion. We also used Baby Hamster Kidney cells,
heterologously expressing F508 CFTR, to determine if SERCA in-
hibitors could interfere with the interaction between calnexin and
CFTR and thereby correct the F508 CFTR misfolding defect. Finally,
at the whole animal level, we tested the ability of curcumin and
thapsigargin to (1 ) induce Cl secretion and reduce hyperabsorp-
tion of Na in the nasal epithelia of the F508 mouse in vivo, and
(2 ) induce Cl secretion in intestine (jejunum and distal colon) and
the gallbladder of the F508 CF mouse. We conclude that curcumin
and thapsigargin failed to induce maturation of F508 CFTR, or
induce Cl secretion, as measured by biochemical and electrophysi-
ologic techniques in a variety of model systems ranging from cul-
tured cells to in vivo studies.
Keywords: F508 CF mouse; CFTR trafficking; Cl channel; curcumin
The F508 mutation is the most common cystic fibrosis (CF)
mutation and results in the deletion of phenylalanine at the
508 position in the CF transmembrane conductance regulator
(CFTR) protein (1). Abnormal processing of the F508 CFTR
protein leads to its retention in the endoplasmic reticulum (2)
and ultimately rapid intracellular degradation. Failure to reach
the plasma membrane is largely responsible for the inability of
F508 CFTR to function as a cAMP activated Cl channel (3).
However, under specific experimental conditions, such as low
temperature or addition of chemical chaperones, trafficking of
F508 CFTR to the plasma membrane can be enhanced (2–4).
Although the ion channel properties of F508 CFTR are not
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identical to those of wild-type (WT)-CFTR, the magnitude of
normal F508 CFTR trafficking produced by these maneuvers
may be sufficient to partially restore Cl secretion to the CF
epithelium (2–4).
It has been previously reported that sarcoplasmic/endoplasmic
reticulum calcium (SERCA) pump inhibitors decrease the cal-
cium concentration within the endoplasmic reticulum (ER), in-
terfering with the ability of Ca-dependent chaperone proteins
to retain the misfolded protein in the ER (5). It has been sug-
gested that blockade of this chaperone interaction allows mis-
folded F508 CFTR to escape from the ER, localize to the cell
surface, and function as a Cl channel (6).
Recently, it has been reported that the low-affinity SERCA
pump inhibitor (curcumin), after oral administration, corrects
the abnormal nasal and rectal PDs of F508 homozygous CF
mice (6). In addition to the observed electrophysiologic correc-
tion, the F508 CF mice treated with curcumin (in a 10-wk
study) gained weight and exhibited normal survival compared
with untreated 508 CF mice. The authors also reported that
curcumin treatment of baby hamster kidney (BHK) cells, heter-
ologously expressing F508 CFTR, produced plasma membrane
localization and Cl channel function of the F508 CFTR pro-
tein (6). A study by Dragomir and coworkers reported a small
but significant Cl efflux in F508 CFTR expressing BHK cells
treated with curcumin (7). The authors of this study concluded
that since comparable experiments failed to demonstrate an
effect of curcumin on F508 CFTR airway epithelial cells, the
BHK observation was likely due to the overexpression artifact of
this model system. Likewise, other researchers have investigated
this curcumin-mediated phenomenon and reported no evidence
for curcumin-induced correction of F508 CFTR trafficking
(7–10). However, none of these studies have carefully replicated
the original methods and used all of the model systems reported
by Egan and colleagues (5, 6).
Because curcumin or other SERCA pump inhibitors have
been proposed as a validated therapeutic class for CF therapy,
we have investigated the effect of SERCA pump inhibitors (cur-
cumin and thapsigargin) at multiple levels. At the molecular
level, we investigated: (1) the interaction between the Ca-
dependent chaperone calnexin and wild-type CFTR; and (2) the
ability of these compounds to produce mature F508 CFTR
protein. At the cellular/tissue level, the efficacy of these two
SERCA pump inhibitors to induce Cl secretion in cultured CF
human bronchial epithelia was investigated. Finally, at the whole
animal level, we tested the ability of curcumin to (1) induce
Cl secretion and reduce hyperabsorption of Na in the nasal
epithelia of the F508 CF mouse in vivo; and (2) induce Cl
secretion in the intestine (jejunum and distal colon) and the




BHK. Baby hamster kidney (BHK-21) cells expressing F508 CFTR
or extope F508 CFTR were grown at 37C in 5% CO2 as described
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previously (11). To allow maturation of the mutant protein, BHK-21
cells expressing Extope-F508 CFTR were grown at 27C for 2 d in the
presence of 2 mM butyrate. For comparison, BHK-21 cells expressing
Extope-CFTR were grown under the same conditions.
Human airway epithelial cells. Bronchial specimens were obtained
from donor and CF patients (F508) at transplantation, and epithelial
cells isolated, cultured, and studied at 27–28 d, as previously described
(12).
Immunoblotting. Cells were washed in ice-cold phosphate-buffered
saline (PBS) and lysed with NP-40 lysis buffer (1% NP-40, 150 mM NaCl,
50 mM Tris, pH 7.4, 10 mM NaMoO4) at 4C for 30 min. Protease
inhibitors were added to NP-40 lysis buffer to a final concentration of
1 g/ml leupeptin, 2 g/ml aprotinin, 50 g/ml Pefabloc, 121 g/ml
benzamidine, and 3.5 g/ml E64. Cell lysates were centrifuged at maxi-
mal speed in an Eppifuge at 4C, and supernatants were collected. Cell
lysates (25 g) were loaded, separated on 6% SDS-PAGE minigels, and
transferred to nitrocellulose. Blots were probed with anti-CFTR antibody
596 (1:2,000), anti-calnexin antibody SPA-860 (Stressgen, Ann Arbor,
MI), anti-CFTR monoclonal mouse antibody M3A7, or rabbit anti-
calnexin antibody SPA-860.
Immunoprecipitation of the CFTR–calnexin complex. BHK lysates
were prepared as described above. Soluble fractions of the lysates were
incubated with protein G beads coupled with anti-CFTR antibody 596.
The immunocomplexes were washed and eluted with 50 mM Tris-HCl,
pH 6.8, and 1% SDS. The protein components of the complexes were
separated by SDS-PAGE. CFTR and calnexin were detected by
immunoblot.
SERCA inhibitors. Curcumin (VitaminShoppe.com) was diluted in
a stock DMSO solution and a 0.1% concentration added to both the
luminal and serosal surface of cultures for the designated intervals
(3 or 24 h). Airway cells were treated for 3 h with 0–50 M curcumin,
followed by incubation for 3 h in regular medium or treated for 24 h
with 0 or 50 M curcumin. Airway cells were also exposed to 1 M
thapsigargin (Molecular Probes, Eugene, OR) for 1.5 h, followed by a
2-h incubation in regular media, or treated for 24 h.
Primary airway epithelial cell cultures. Human lung tissue (7 non-
CF and 7 CF lungs) was procured under a protocol approved by the
University of North Carolina Committee on the Protection of the Rights
of Human Subjects. Epithelial cell harvest and culture was performed
as previously described (13). All primary CF airway epithelial cells used
in this study were genotyped as F508/F508 by usual clinical testing
methods. Cryopreserved passage 1 cells were cultured in bronchial
epithelial growth medium on Vitrogen-coated plastic dishes (14). At
75–90% confluence, passage 2 cells were transferred to type IV collagen-
coated Snapwell membranes (Corning Costar, Cambridge, MA) for
use in Ussing chambers, or 30-mm-diameter Millicell CM membranes
(Millipore, Bedford, MA) for biochemical studies. Beginning at Days
4–7, visibly confluent cultures were maintained at an air–liquid interface
(ALI) (14). Human airway epithelial cultures grown under these condi-
tions demonstrate a well-differentiated histology. Furthermore, those
cultured that generated a transepithelial resistance (Rt) of at least
200 cm2, after the resistance of the permeable support was subtracted,
were used for Ussing chamber studies. Typically, these criteria were
achieved at 14–21 d after plating onto Snapwell inserts. Rt was not
different between WT and CF monolayers, nor was Rt affected by
exposure to curcumin at any dose for any length of time.
Well-differentiated ALI cultures were treated with varying concen-
trations of curcumin in DMSO (0.05–0.1%) or vehicle alone for the
indicated time periods. For the majority of the experiments, the cur-
cumin was from Fluka (Steinheim, Switzerland), but in a subset of
experiments an alternative source of curcumin was used (AFI curcuma-
noids, Piscataway, NJ).
Electrical measurements. Electrical measurements (i.e., Rt, transepi-
thelial potential [Vt], and short-circuit current [Isc]), were made on cell
monolayers mounted in Ussing chambers, as previously described (12).
Monolayers were bathed in a bilateral Krebs Bicarbonate Ringer solu-
tion (KBR) bubbled with 95% O2, 5% CO2 and maintained at 37C. Vt
was clamped to zero, and pulsed to  10 mV for 0.5 s every 60 s. The
electrometer output was digitized online and Isc, Rt, and calculated Vt
were displayed on a video monitor and stored on a computer hard
drive. Drugs were added from concentrated stock solutions to either
lumenal and/or serosal surfaces of the tissue.
In Vivo and In Vitro Murine Studies
Most of the F508 CF mice (Cftrtm1Kth) (congenic C57BL6/J) were ob-
tained from the colony at Case Western Reserve University. However,
a small number of F508 CF mice were obtained from the colony at
Yale University. Most of the wild-type control mice were littermates
to the CF mice. However, as we lacked several wild-type mice, these
controls were obtained from Jackson Laboratory (Bar Harbor, ME)
and were strain- (C57BL/6J), age-, and sex-matched. All mice were
maintained on a high-fat diet (9%) and given Colyte in place of water.
The genotypes of all mice were confirmed by PCR.
Curcumin dosing In vivo. The mice were dosed orally three times
per day (45 mg/kg) for 3 d at  8-h intervals with curcumin (Curcumi-
noids [AFI lot number A20132]; VitaminShoppe.com). This is the same
source, lot number, and curcumin dose as used to obtain the
in vivo data reported by Egan and coworkers (6) (personal communica-
tion with Dr. Egan). The curcumin was removed from the capsule and
suspended in infant formula (Alimentum; Ross Pediatrics, Abbot Park,
IL). Each dose was suspended in an  25-l volume (per 20 g mouse
body mass) of the infant formula and given orally by pipette. The
mice readily swallowed the formula and virtually all the curcumin was
ingested. The control mice were dosed identically except that the Ali-
mentum contained no curcumin. Exactly 2 h after the final dose, the
nasal PDs were measured. This dosing regime and source of curcumin
(and lot number) reflected personal communications with Egan and
Caplan subsequent to the publication of their study, and some aspects
of the protocols varied from those originally published.
Nasal PD. For the nasal PD measurements, the mice were anesthe-
tized with a combination of ketamine/xylazine (86.95 mg/kg and 9.89
mg/kg, respectively). The body temperature of the mouse was continu-
ally monitored with a rectal thermocouple (Physitemp, Clifton, NJ) and
maintained at 37C with a heat lamp. All details of the nasal PD tech-
nique have been previously published (15), the only modification being
that the perfusion flow rate was reduced to 0.5 l/min. When solutions
were switched, the new solution reached the mouse’s nose within  1.5
min. The normal and low Cl buffers have been described previously.
Amiloride (104 M) and isoproterenol (105 M) were made fresh daily,
and added to the buffers as indicated. Continuous recording of the PD
tracing is necessary to obtain an accurate measurement of PD response
times when solutions are changed. In particular, continuous trace re-
cordings are valuable in distinguishing between signal and noise re-
sponses after a solution change. All of the experiments reported in this
study were performed by continuous trace recording. In contrast, the
study by Egan and colleagues (6) did not routinely use continuous
recording (M. Egan, personal communication).
Ussing chamber studies. Immediately after nasal PDs were mea-
sured, the mice were killed with an anesthetic overdose and the distal
colon, jejunum, and gallbladder were removed for Ussing chamber




When BHK 21 cells stably expressing F508 CFTR or an epitope-
tagged CFTR variant (EX-508) were grown in the presence of
0, 20, and 40 uM curcumin for 18 h, we found no evidence of
mature F508 CFTR in any of the curcumin-treated prepara-
tions (Figure 1A). Neither the unmodified F508 CFTR nor the
epitope-tagged version showed any detectable maturation as a
consequence of the curcumin exposure. In contrast, the Ex
F508 cells grown at 27C for 48 h exhibited mature F508
CFTR (Figure 1B), demonstrating that low temperature was
able to partially circumvent the F508 CFTR folding defect.
Thus, the tagged version of F508 CFTR is able to detect condi-
tions that promote maturation.
Next, we tested the hypothesis that curcumin mediates F508
CFTR maturation by interfering with the interaction of a Ca2-
dependent ER chaperone, calnexin, with F508 CFTR. After
incubation of BHK cells expressing Ex-F508 with curcumin
(0–50 M, for either 3 or 18 h), cell lysates were first precipitated
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Figure 1. Effect of curcumin on F508 CFTR expression
and interaction with calnexin. (A ) BHK-21 cells stably ex-
pressing F508 CFTR or Extope-F508 CFTR (Ex-F508),
an epitope-tagged variant, were grown in the presence of
0, 20, and 40 M curcumin for 18 h. Cell lysates were
separated by SDS-PAGE, transferred to nitrocellulose, and
detected with mouse monoclonal anti-CFTR antibody 596.
Wild-type CFTR is shown in the left lane (WT). (B ) Lysates
of Extope-F508 CFTR-expressing cells grown at 37C or
27C for 48 h. (C ) Cells were grown in the presence of 0
and 50 M curcumin for 3 h, followed by incubation for
3 h in regular media or in the presence of 0, 15, and
25 M curcumin for 18 h. F508 CFTR was immunoprecip-
itated (IP) from cell lysates by anti-CFTR mAb 596 cross-
linked to protein G–coupled Dynabeads. Calnexin inter-
acting with immunoprecipitated CFTR was detected by
immunoblotting (IB) with rabbit anti-calnexin antibody
SPA-860 (Stressgen). The same cell lysates were analyzed
by immunoblotting using anti-CFTR monoclonal mouse
antibody M3A7 (D ) or rabbit anti-calnexin antibody SPA-
860 (E ) to detect F508 CFTR and calnexin, respectively.
by an anti-CFTR antibody and then blotted for expression of
calnexin using a calnexin-specific antibody (Figure 1C). None
of the curcumin doses tested significantly reduced the CFTR–
calnexin interaction, nor did they result in F508 CFTR maturation
(Figure 1D) or alteration of free calnexin levels (Figure 1E).
Egan and colleagues have shown in an earlier article (6) that
another SERCA inhibitor (thapsigargin) also mediated similar
efficacy in correcting the F508 CFTR maturation defects (5).
We therefore examined the ability of thapsigargin to induce
F508 CFTR maturation in BHK cells as well as its ability
to interfere with calnexin binding (Figure 2). Using doses and
incubations identical to those used by Egan and coworkers (6),
we detected no maturation of F508 CFTR as measured by the
lack of a fully gylcosylated band “c” (Figure 2A), alteration in
the co-precipitation pattern of F508 CFTR with calnexin (Fig-
ure 2C), or difference in the blotting patterns for F508 CFTR
(Figure 2B) compared with calnexin (Figure 2C). Thus, neither
SERCA inhibitor (curcumin or thapsigargin) promoted matura-
tion of nascent F508 CFTR by dissociation from calnexin, nor
by other means. Indeed, F508 CFTR did not progress beyond
the ER, even when calnexin binding was completely prevented
by glycosylation inhibitors or by mutagenesis (M. Gentzsch, un-
published observations). Thus, in addition to the probable lack of
specificity of targeting CFTR/calnexin interactions, the strategy
appears to be ineffective in the case of F508 CFTR.
Cultured Airway Epithelial Studies
We next studied the effect of curcumin on forskolin-stimulated
Cl secretion by cultured primary human airway epithelia (nor-
mal and F508 CF) in Ussing chambers. The curcumin doses
chosen (0–50 uM, 3 or 24 h) spanned the dose ranges reported
to be effective by Egan and colleagues (6). Representative traces,
shown in Figure 3A, demonstrate the lack of a forskolin-stimulated
Cl current following the incubation of cultured CF airway epi-
thelia with curcumin. In contrast, normal (WT) airway cultures
exhibit a robust response to forskolin (Figure 3A). Summary
data reveal that normal (WT) airway cells exhibited a robust
forskolin response and that curcumin was without effect in F508
airway cells (Figure 3B). Biochemical analyses of F508 airway
cells exposed to the same doses of curcumin for either 3 or 24 h
failed to detect mature F508 CFTR (Figure 3C).
Identical experiments were performed with thapsigargin, us-
ing a dose and incubation time identical to that reported in an
earlier study by Egan and coworkers (5). This compound also
failed to induce Cl secretion in response to forskolin addition
in F508 cells, whereas normal airway cells exhibited the typical
secretory response to forskolin (Figure 4A). Also note that the
subsequent UTP-mediated Cl secretion is greatly reduced fol-
lowing exposure to thapsigargin (consistent with depletion of
intracellular Ca2 stores). Immunoprecipitation and immuno-
blotting again indicated that no mature F508 CFTR was present
in the thapsigargin-treated F508 cells (Figure 4C). Moreover,
F508 CFTR band “B” appears to be significantly reduced by
this exposure to thapsigargin.
In Vivo Studies
The basal in vivo PDs in the F508 CF mice receiving vehicle
alone were significantly raised compared with the basal PDs of
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Figure 2. Effect of thapsigargin on F508 CFTR expression
and interaction with calnexin. (A ) F508 CFTR–expressing
BHK cells were treated with 10 M thapsigargin for 0, 1.5,
or 24 h () or left untreated (). Western blot of lysates,
including untreated WT, is shown. (B ) Cells were grown in
1 or 10 M thapsigargin for 1.5 or 24 h. F508 CFTR was
immunoprecipitated from the cell lysates and immunoblot-
ted with anti-CFTR as in A. (C ) Same blot probed with anti-
calnexin, showing that amount of CFTR-associated calnexin
reflects amount of CFTR.
the WT mice (Figures 5 and 6A). No reduction of the CF-specific
raised PD was observed after curcumin treatment (Figures 5
and 6). As a control for nonspecific effects of curcumin on nasal
PD, a group of WT mice were also dosed with curcumin, and
the bioelectric data did not differ from that of the WT mice
receiving vehicle treatment (data not shown). As a second mea-
sure of the Na transport rate, amiloride was included in the
PD perfusate. Again, the amiloride-sensitive PD response of
vehicle-exposed F508 CF mice was significantly greater than
that of WT mice, and curcumin treatment of CF mice was without
effect (Figures 5 and 6B). Collectively, these data indicate that
curcumin did not slow the Na hyperabsorption that is a hall-
mark of CF airways disease (16).
The nasal epithelium of the normal mouse exhibits a large
apical membrane Cl conductance. This pathway may be exam-
ined in vivo by luminal Cl substitution (containing amiloride),
which typically results in a significant hyperpolarization of the
nasal PD (Figures 5A and 6C). The vehicle-treated F508 CF
mice exhibited a small depolarization in the post-amiloride PD,
which differed significantly from that of the WT mice. The
curcumin-treated CF mice exhibited Cl substitution responses
virtually identical to those of vehicle-treated CF mice. Following
the low Cl response, isoproterenol (104 M) was added to the
perfusate. All three groups of mice exhibited a small hyperpolar-
ization (mV, WT 1.8  0.73 [10], F508 CF vehicle treatment
3.5  2.0 [2], and F508 CF curcumin RX 1.08  0.8 [3]) in
response to the isoproterenol perfusion that did not differ sig-
nificantly among the three groups. Three additional F508 mice
were dosed with curcumin (45 mg/kg) for 5–7 d and PDs mea-
sured 6–8 h after the final dose. This experimental alteration
was designed to allow for the possibility of a longer curcumin-
mediated transit time for CFTR maturation. The longer incuba-
tion period had no effect on basal PD, amiloride-sensitive PD,
or Cl secretion (data not shown). Additional F508 CF mice
were obtained from the Yale colony (same strain as used by
Egan and coworkers [6]) and studied at Case Western Reserve
University following the dosing protocol described in our paper.
Nasal PDs were studied before and after curcumin treatment in
these mice. These studies indicated that there was no evidence
of a correction in the Cl transport defect in response to the
curcumin treatment (Cl diffusion potential 0.47  0.43 mV
before curcumin treatment and 0.3  0.99 mV after curcumin
treatment; P  0.54, n 	 5). Together, these data confirm that
CF mice exhibit defective apical membrane Cl conductance
and Na hyperabsorption and that curcumin did not modify
these defects.
Murine In Vitro Studies
After the PD measurements, the mice were killed, and tissues
were immediately excised and mounted on Ussing chambers.
The WT jejuna exhibited a robust Cl secretory response (Isc
in response to forskolin [17]), whereas the forskolin response
exhibited by the tissue from the vehicle- or curcumin-treated
F508 CF mice did not differ from zero (Figure 7A). The distal
colon from the WT mice also exhibited a robust Cl secretory
response to forskolin, whereas the colons from both the vehicle-
and curcumin-treated F508 CF mice exhibited a small response
of reversed polarity, likely reflecting K secretion (18) (Figure
7B). The gallbladders of the WT mice also exhibited a significant
forskolin induced Cl secretory response, whereas neither
vehicle- nor curcumin-treated F508 CF mice exhibited signifi-
cant responses to forskolin (Figure 7C). In no study was there
a difference in response between the curcumin- and vehicle-
treated F508 CF mice.
Finally, PD studies and Ussing chamber studies (intestine
and gallbladder) were repeated on vehicle- or curcumin-treated
UNC-null CF mice (CFTRtm1Unc) and WT control mice. Again,
curcumin was completely without effect and responses of the
curcumin-treated CF mice did not differ from those of vehicle-
treated CF mice, whereas both groups of CF mice differed sig-
nificantly from WT (data not shown).
DISCUSSION
An article recently published by Egan and colleagues reported
that curcumin given to F508 CF mice in doses similar to those
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Figure 3. Effect of curcumin
on normal and F508 human
airway epithelial cultures. (A )
Representative Isc responses of
WT and CF human airway epi-
thelial cultures exposed to cur-
cumin. WT (upper line) and CF
(lower two lines, solid and
dashed) well-differentiated cul-
tures were exposed to either
vehicle, 0.1% DMSO (solid
lines), or 50 M curcumin
(dashed line) for 24 h before
mounting in Ussing chambers.
(B ) Dose–effect studies in
F508 CF airway epithelia of
curcumin (3 h or 24 h expo-
sures; 0–50 M) on forskolin-
stimulated Cl secretion. Doses
used spanned the dose range
reported by Egan and cowork-
ers (6). Histobars represent the
mean  SEM of at least six dif-
ferent human airway epithelial
cultures from at least three dif-
ferent donor tissue samples for
each dose tested. In a separate
series of experiments, genistein
(100 M) was added to en-
hance the forskolin-stimulated
current; no significant differ-
ence was detected between
nontreated and curcumin-
treated cultures (n 	 4). WT
(normal control) response de-
picted in the open bar. (C ) Bio-
chemical analyses of human
airway epithelia exposed to
curcumin. CFTR was immuno-
precipitated and immobilized
with anti-CFTR mAb 596 as in
Figure 1, separated by SDS-
PAGE, and transferred to nitro-
cellulose, which was probed
with the same antibody.
which can be safely administered to humans induced striking
corrections of ion transport in F508 CF mice (6). This article
had important clinical implications for treatment of patients with
CF, but there were divergent opinions as to the implementation
of a clinical development program. As a result of this article,
some advocated clinical trials with curcumin on patients with
CF (19, 20). Others suggested that the data must first be indepen-
dently replicated and confirmed (21, 22). We and others opted
to undertake a comprehensive study to examine on the efficacy
of SERCA compounds on reversing the trafficking/transport
defect of F508 CFTR.
Egan and coworkers (6), using BHK cells as a heterologous
host for human WT and F508 CFTR expression, reported that
curcumin induced a modest maturation of F508 CFTR, which
they suggested reflected blockade of the interaction of the Ca-
dependent ER chaperone calnexin with F508 CFTR. A more
recently published study failed to find a significant effect of
curcumin or thapsigargin on F508 CFTR maturation in BHK
cells (9). In control experiments, these investigators found that
incubating F508 CFTR–expressing BHK cells for 18 h at 27C
markedly increased the yield of mature F508 CFTR protein
(9). Another study, employing F508-BHK and a human CF
airway epithelial cell line (CFBE), reported that curcumin treat-
ment caused no noticeable trafficking of F508 CFTR to the
plasma membrane (7). Likewise, our studies revealed no evi-
dence of curcumin- or thapsigargin-induced F508 CFTR matu-
ration, and we extended previous studies by failing to detect
interactions between calnexin and F508 CFTR protein
(Figures 1 and 2).
Because ultimately the importance of SERCA pump inhibi-
tors (curcumin) as therapeutic agents will be reflected in organ
level function, we measured the Cl secretory as well as biochem-
ical correlates of curcumin and thapsigargin administration in a
well-differentiated human bronchial epithelial culture system
that has been useful in predicting efficacy of other forms of
therapy in vivo (23, 24). We detected neither bioelectric evidence
of forskolin-induced activation of F508 CFTR chloride secre-
tory currents in curcumin- or thapsigargin-treated cultures, nor
any evidence that curcumin or thapsigargin induced maturation
of F508 CFTR protein in these cultures (Figures 3 and 4).
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Figure 4. Effect of thapsigar-
gin on normal and F508 hu-
man airway epithelial cultures.
(A ) Representative Isc responses
of WT and CF human airway
epithelial cultures exposed to
thapsigargin. WT (upper line)
and CF (lower two lines, solid
and dashed) well-differentiated
cultures were exposed to either
vehicle, 0.1% DMSO (solid
lines), or 1 M thapsigargin
(dashed line) for 90 min before
mounting in Ussing chambers.
(B ) Duration–effect (1.5 h;
24 h) studies of thapsigargin
(1 M) on forskolin-stimulated
Cl secretion in homozygous
F508 human airway epithelia.
Thapsigargin dose and times
span those reported by Egan
and coworkers in heterologous
systems (5). Histobars depict
mean  SEM of at least six dif-
ferent cultures from two donor
samples. (C ) Cells were treated
with 1 M thapsigargin for 1.5
or 24 h or with vehicle control
(0.1% DMSO) for 24 h, lysed,
and analyzed by sequential im-
munoprecipitation and immu-
noblotting, as in Figure 3C. Re-
sults with normal airway cells
expressing wild-type CFTR
(WT) are shown in the left lane.
Again, the doses and duration of exposure spanned, or even
exceeded, those reported by Egan and colleagues in murine or
BHK cell systems (6). Further, our techniques detected large
forskolin-induced Cl secretory currents in WT cells (Figures
3A and 4A), and our highly sensitive immunoblots or immuno-
Figure 5. Nasal PD recorder traces. Representative PD traces from WT mouse (A ), F508 CF mouse given vehicle (B ), and a F508 CF mouse
treated with curcumin (C ). Amiloride, 104 M, (Amil) was added at the times indicated. Then, the system was switched to a 0 chloride plus
amiloride buffer (0 Cl), and finally, isoproterenol (105 M) (Iso) was added to the 0 Cl plus amiloride buffer at the times indicated.
precipitates from these cultures detected distinctive immature
F508 CFTR protein bands both in the absence and presence
of these agents (Figures 1–4).
Others have also reported negative results on the effect
of curcumin on human CF airway cells. Song and coworkers
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Figure 6. Mean nasal PD data. (A ) Mean basal PD in WT, F508 CF vehicle-treated, and F508 CF mice treated with curcumin. (B ) Change in
PD in response to amiloride. (C ) Change in PD in response to low Cl substitution. All bars are means  SEM. Open bars are WT mice (n 	 10),
hatched bars are F508 CF mice given vehicle (n 	 5), and filled bars are F508 CF mice treated with curcumin (n 	 7).
reported that curcumin treatment failed to induce a forskolin-
mediated Cl secretion in primary human airway cells homozy-
gous for F508 CFTR (10). As a control, these investigators
reported that F508 CFTR human cells grown at 27C responded
to forskolin with a substantial increase in Isc (10). Similarly,
Dragomir and colleagues reported that curcumin failed to induce
a forskolin-mediated Cl efflux in either CFBE cells or CF nasal
epithelial cells (7). However, they did report a small increase in
net cAMP-activated Cl efflux after curcumin treatment of
F508 CFTR BHK cells (7). Berger and coworkers reported
that in human CF bronchus (homozygous F508) curcumin
treatment failed to induce a response to forskolin in the CF
preparations when studied in Ussing chambers (8). However,
these investigators did report an acute effect of curcumin on
WT CFTR channel activity measured by inside-out membrane
patch clamp (8). Finally, in a heterologous expression system,
Fischer rat thyroid cells expressing F508 CFTR, exposure to
curcumin (1–40 M up to 24 h incubation) showed no evidence
of an enhanced iodide influx compared with the untreated F508
CFTR cells (10).
Egan and colleagues detected only modest maturation of
F508 CFTR as a result of curcumin treatment. Conceivably,
our failure to detect maturation of CFTR, either by immuno-
chemistry in BHK or airway cells or by Cl transport in the
human airway epithelium, could reflect a sensitivity issue. The
large dynamic range for Cl secretion in our culture assay (Fig-
ures 3 and 4), and the very high sensitivity of the newer anti-
CFTR monoclonal antibodies (25), argue against this possibility.
An approach to more directly test the sensitivity issue was
to study curcumin effects in mice because of the striking magni-
tude of curcumin-induced correction in the F508 CF mouse
reported by Egan and coworkers (6). First, we attempted to
Figure 7. Change in
short circuit in response
to forskolin for freshly
excised tissue studied
on the Ussing chamber.
(A ) Forskolin response
of WT, F508 CF
vehicle-treated, and
F508 CF curcumin-
treated jejuna. (B ) For-
skolin response of distal
colons. (C ) Forskolin
response of gallbladders. All bars are means  SEM. Open bars are WT mice (n 	 8), hatched bars are F508 CF mice given vehicle (n 	 3), and
filled bars are F508 CF mice treated with curcumin (n 	 6).
reproduce the data of Egan and coworkers demonstrating
curcumin-induced correction of sodium transport in the nasal
cavity, but we could find no evidence that curcumin corrected
Na hyperabsorption in the F508 CF mouse (Figure 6B). More-
over, we used a spectrum of protocols, varying the doses and
duration of curcumin treatment, but detected no evidence that
curcumin corrected chloride transport in the nasal cavity of
F508 CF mice (Figure 6C). Finally, the in vivo PD studies of Cl
transport in vehicle- versus curcumin-treated F508 CF mice,
conducted at Case Western Reserve University, produced simi-
lar negative results. The absence of curcumin-induced nasal Cl
transport is consistent with a recent report of Song and colleagues
showing no correction of the nasal epithelial Cl secretion in
curcumin-treated F508 CF mice (10). In the study by Song and
coworkers (10), serum curcumin was measured 2 h after dosing
mice at 15 mg/kg. At this dose, no detectable serum curcumin
was found. However at a dose of 100 mg/kg, 2 h after dosing,
very low levels of curcumin (36 nm) were detected (10), indicat-
ing very low levels of curcumin bioavailabilty.
It is difficult to reconcile the unequivocally negative results
obtained in the present investigations (as well as those in the
literature) with the strikingly positive results obtained in the
study by Egan and colleagues. We would emphasize that our
studies in CF mice spanned the doses and duration originally
described in that study (6), and we expanded the studies (after
consultation with the authors) to include other sources of cur-
cumin, extended durations of dosing, and the apparent require-
ment to measure the in vivo PD within 2 h of the last dosing.
Most of the F508 CF mice in our studies were of the same
genetic background, but the strain backgrounds were slightly
different than those studied by Egan and coworkers (UNC/
CWRU: congenic C57BL/6; Egan and colleagues: C57BL/6 with
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 25% 129 SvEv). However, we also obtained F508 CF mice
from the Yale colony. The nasal bioelectrics of these mice were
also not corrected with curcumin treatment. The mice used for
the in vivo PD studies by Song and coworkers (10) were on a
CD1 genetic background. The strain differences do not, there-
fore, appear to explain the disparity in the data. Possibly with
respect to the PD recording, technical issues—for examples,
continuous (UNC) versus intermittent PD recording (M. Egan,
personal communication)—may be the more relevant technical
differences (see Materials and Methods).
Because Egan and colleagues reported that curcumin cor-
rected abnormal rectal PDs, produced weight gain, and ex-
tended survival of F508 CF mice, we performed extensive Uss-
ing chamber studies to determine whether we could reproduce
the correction of Cl transport of the GI tract in curcumin-
treated F508 CF mice. Again, we could find no evidence of
even a minimal restoration of Cl transport in jejuna, distal
colon, or gallbladders after curcumin treatment. It is possible
that the improved weight gain and extended survival of the
curcumin-treated mice reported by Egan and coworkers (6) may
have been due to a laxative effect of the curcumin (or Alimentum
alone), as no vehicle controls were performed in their study.
However, this difference would not explain the reported correc-
tion of rectal PD of the F508 mice in the curcumin-treated
mice reported by Egan and colleagues.
It may not be surprising that we observed no correction in
the intestine of the F508 CF mouse, since the mice that we
(and Egan’s group) studied have a marked decrease in F508
CFTR mRNA compared with the F508 CFTR mRNA levels
in other tissues as well as compared with WT CFTR mRNA in
the intestine (27). This finding, coupled with the report that
curcumin treatment resulted in surface expression of F508
CFTR (BHK cells) that was only 25% of that obtained after
low-temperature incubation (6) (we found none), would suggest
that little if any F508 CFTR would be localized to the plasma
membrane of enterocytes in curcumin-treated F508 CF mice.
Our results, performed in three separate institutes, employing
several different model systems (a heterologous cell system, hu-
man F508 CF primary cells, and F508 CF mice), with high
sensitivity and positive controls (e.g., low temperature), demon-
strated that SERCA pump inhibitors are not effective in traffick-
ing F508 CFTR to the membrane and correcting function in
CF tissue. Given our results, coupled with the data in the litera-
ture that fail to detect any effect of curcumin in correcting trans-
port defects associated with F508 CFTR, we would suggest
that it is premature to examine the efficacy of curcumin in CF
human clinical trials.
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